Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
7
Frequently Asked Questions
What is market cap of Context Therapeutics Inc?
The market cap of Context Therapeutics Inc is $9.88M
What is the 52 week high for Context Therapeutics Inc?
The 52 week high for Context Therapeutics Inc is $2.79.
What is the 52 week low for Context Therapeutics Inc?
The 52 week low for Context Therapeutics Inc is $0.60.
What is Context Therapeutics Inc stock price today?
Context Therapeutics Inc' stock price today is $0.6301.
What is the pe ratio of Context Therapeutics Inc?
The PE ratio of Context Therapeutics Inc is -0.69.
What is the price to book ratio of Context Therapeutics Inc?
The price to book ratio of Context Therapeutics Inc is 0.2594.
What is Context Therapeutics Inc's EBITDA?
Context Therapeutics Inc's EBITDA is -14.58757.
What is the 50-day moving average of Context Therapeutics Inc?
The 50-day moving average of Context Therapeutics Inc is 0.7861.
How many employess does Context Therapeutics Inc has?